|
|
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- NHS Trusts (England) - Chief Executive
- Out of hours contacts
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- Special Health Authorities
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
|
| Title: |
|
Interleukin-6 inhibitors (tocilzumab or sarilumab) for patients hospitalised due to COVID-19
|
| Broadcast content: |
|
***31 January 2022. This alert has been updated***
This alert replaces the previous alert CEM/CMO/2021/006 issued on 17th February 2021.
A single UK Interim Clinical Commissioning Policy has now been published, recommending that equal consideration is given to two potential interleukin-6 (IL-6) inhibitor treatment options - tocilizumab or sarilumab - for adult patients (aged 18 years and older) hospitalised due to COVID-19 in accordance with the agreed criteria.
The combined policy replaces previous separately published policies for sarilumab and tocilizumab respectively.
|
| Additional information: |
|
This alert is not relevant to Primary Care.
|